CytomX Therapeutics, Inc. Operating Cash Flow
CytomX Therapeutics, Inc. (CTMX) reported Operating Cash Flow of -$43.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$18.07M.
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$25.55M.
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$23.24M.
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$15.55M.
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$75.59M.
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$86.23M.
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$56.03M.
- CytomX Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$110.79M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$18.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$43.62M 10-Q · filed 2026-08-06 | -$66.86M derived: sum of 3 quarters · filed 2026-08-06 | -$82.41M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$25.55M 10-Q · filed 2026-05-07 | -$48.79M derived: sum of 2 quarters · filed 2026-05-07 | -$64.34M derived: sum of 3 quarters · filed 2026-05-07 | -$80.09M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$23.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$38.79M derived: sum of 2 quarters · filed 2026-03-16 | -$54.54M derived: sum of 3 quarters · filed 2026-08-06 | -$75.59M 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$15.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$31.30M derived: sum of 2 quarters · filed 2026-08-06 | -$52.34M 10-Q · filed 2025-11-06 | -$72.25M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$15.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$36.80M 10-Q · filed 2026-08-06 | -$56.70M derived: sum of 3 quarters · filed 2026-08-06 | -$77.43M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$21.04M 10-Q · filed 2026-05-07 | -$40.95M derived: sum of 2 quarters · filed 2026-05-07 | -$61.68M derived: sum of 3 quarters · filed 2026-05-07 | -$81.23M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$19.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$40.64M derived: sum of 2 quarters · filed 2026-03-16 | -$60.19M derived: sum of 3 quarters · filed 2026-03-16 | -$86.23M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$20.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$40.28M derived: sum of 2 quarters · filed 2025-11-06 | -$66.32M 10-Q · filed 2025-11-06 | -$88.29M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$19.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$45.59M 10-Q · filed 2025-08-07 | -$67.56M derived: sum of 3 quarters · filed 2025-08-07 | -$85.80M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$26.05M 10-Q · filed 2025-05-12 | -$48.01M derived: sum of 2 quarters · filed 2025-05-12 | -$66.25M derived: sum of 3 quarters · filed 2025-05-12 | -$91.43M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$21.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$40.21M derived: sum of 2 quarters · filed 2025-03-06 | -$65.38M derived: sum of 3 quarters · filed 2025-03-06 | -$56.03M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$18.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$43.42M derived: sum of 2 quarters · filed 2024-11-07 | -$34.07M 10-Q · filed 2024-11-07 | -$35.47M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$25.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$15.83M 10-Q · filed 2024-08-08 | -$17.22M derived: sum of 3 quarters · filed 2024-08-08 | -$51.07M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $9.35M 10-Q · filed 2024-05-08 | $7.96M derived: sum of 2 quarters · filed 2024-05-08 | -$25.89M derived: sum of 3 quarters · filed 2024-05-08 | -$60.13M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$35.24M derived: sum of 2 quarters · filed 2024-03-11 | -$69.47M derived: sum of 3 quarters · filed 2024-03-11 | -$110.79M 10-K · filed 2024-03-11 | |
| 2022-09-30 | -$33.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$68.08M derived: sum of 2 quarters · filed 2023-11-07 | -$109.39M 10-Q · filed 2023-11-07 | -$109.39M 10-Q · filed 2022-11-08 | -$140.59M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$34.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$75.55M 10-Q · filed 2023-08-08 | -$106.74M derived: sum of 3 quarters · filed 2023-08-08 | -$136.44M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$41.31M 10-Q · filed 2023-05-09 | -$72.50M derived: sum of 2 quarters · filed 2023-05-09 | -$102.20M derived: sum of 3 quarters · filed 2023-05-09 | -$130.40M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$31.19M derived: 10-K/A 12 month − 10-K/A 9 month · filed 2023-03-27 | -$60.89M derived: sum of 2 quarters · filed 2023-03-27 | -$89.09M derived: sum of 3 quarters · filed 2023-03-27 | -$119.03M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | -$29.70M derived: 10-K/A 9 month − 10-K/A 6 month · filed 2023-03-27 | -$57.90M derived: sum of 2 quarters · filed 2023-03-27 | -$87.84M 10-K/A · filed 2023-03-27 | -$105.27M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-06-30 | -$28.20M derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-03-27 | -$58.14M 10-K/A · filed 2023-03-27 | -$75.57M derived: sum of 3 quarters · filed 2023-03-27 | -$100.24M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-03-31 | -$29.94M 10-K/A · filed 2023-03-27 | -$47.37M derived: sum of 2 quarters · filed 2023-03-27 | -$72.05M derived: sum of 3 quarters · filed 2023-03-27 | $25.06M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-12-31 | -$17.43M derived: 10-K/A 12 month − 10-K/A 9 month · filed 2023-03-27 | -$42.10M derived: sum of 2 quarters · filed 2023-03-27 | $55.00M derived: sum of 3 quarters · filed 2023-03-27 | $5.26M 10-K/A · filed 2023-03-27 | |
| 2020-09-30 | -$24.68M derived: 10-K/A 9 month − 10-K/A 6 month · filed 2023-03-27 | $72.42M derived: sum of 2 quarters · filed 2023-03-27 | $22.69M 10-K/A · filed 2023-03-27 | -$6.79M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-06-30 | $97.10M derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-03-27 | $47.36M 10-K/A · filed 2023-03-27 | $17.89M derived: sum of 3 quarters · filed 2023-03-27 | -$5.43M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-03-31 | -$49.74M 10-K/A · filed 2023-03-27 | -$79.22M derived: sum of 2 quarters · filed 2023-03-27 | -$102.53M derived: sum of 3 quarters · filed 2023-03-27 | -$151.19M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2019-12-31 | -$29.48M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | -$52.80M derived: sum of 2 quarters · filed 2023-03-27 | -$101.45M derived: sum of 3 quarters · filed 2023-03-27 | -$140.48M 10-K/A · filed 2023-03-27 | |
| 2019-09-30 | -$23.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$71.97M derived: sum of 2 quarters · filed 2020-11-05 | -$111.00M 10-Q · filed 2020-11-05 | -$139.74M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | -$48.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$87.68M 10-Q · filed 2020-08-06 | -$116.42M derived: sum of 3 quarters · filed 2021-02-24 | -$121.97M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | -$39.03M 10-Q · filed 2020-05-07 | -$67.77M derived: sum of 2 quarters · filed 2021-02-24 | -$73.32M derived: sum of 3 quarters · filed 2021-02-24 | -$99.94M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | -$28.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$34.29M derived: sum of 2 quarters · filed 2021-02-24 | -$60.91M derived: sum of 3 quarters · filed 2021-02-24 | -$75.52M 10-K · filed 2021-02-24 | |
| 2018-09-30 | -$5.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$32.17M derived: sum of 2 quarters · filed 2019-11-07 | -$46.78M 10-Q · filed 2019-11-07 | -$24.78M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | -$26.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$41.23M 10-Q · filed 2019-08-07 | -$19.23M derived: sum of 3 quarters · filed 2020-02-27 | -$24.96M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | -$14.61M 10-Q · filed 2019-05-09 | $7.39M derived: sum of 2 quarters · filed 2020-02-27 | $1.65M derived: sum of 3 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $16.26M derived: sum of 2 quarters · filed 2020-02-27 | $170.37M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | -$5.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $148.37M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $154.11M 10-Q · filed 2018-08-08 | ||||
| 2016-12-31 | -$2.03M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |